Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q1 FY2027 Earnings Presentation
15 slides from Piramal Pharma's earnings presentation, Jul 30, 2026
Slide 1: Q1FY27 Results
yy — yr Piramal Pharma Limited
Slide 2: Disclaimer
Disclaimer E This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner
Slide 3: Performance Highlights
Performance Highlights Piramal Pharma Limited
Slide 4: A Positive Start to FY2027: Momentum Across All Three Businesses
A Positive Start to FY2027: Momentum Across All Three Businesses E “ We have started FY2027 on a strong note. As guided, all the three businesses delivered healthy revenue growth with improvement in EBITDA margins. CDMO Broad-based performance across India and overseas sites; Focus on strong executi
Slide 5: Q1FY27 Financial Performance: Broad-Based Growth & Margin Expansion
Q1FY27 Financial Performance: Broad-Based Growth & Margin Expansion E Revenue from Operations EBITDA EBITDA Margin (In ₹ Crore) (In ₹ Crore) 17 % 72 % 400 bps 2,270 285 12.5% 1,934 165 8.5% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 CDMO CHG PCH (In ₹ Crore) (In ₹ Crore) (In ₹ Crore) 19 % 17 % 15 % 1
Slide 6: CDMO Business: Return to Growth
CDMO Business: Return to Growth E Key Highlights Revenue Performance (In ₹ Crore) Strong start to the year with 19% YoY revenue growth driven by: 19 % ❖ Healthy pick-up in RFPs and order inflows across multiple sites supported by enhanced commercial team and improved win rates • Significant surge in
Slide 7: Advancing our ADC Platform: Capacity, Capability & Partnerships
Advancing our ADC Platform: Capacity, Capability & Partnerships E Building on our integrated ADCelerate platform — 20+ years in ADCs ON TRACK COMPLETED PARTNERSHIP Lexington, US Riverview, US Ajinomoto Bio-Pharma Scaling sterile injectables capacity Commercial manufacturing capability Access to next
Slide 8: Complex Hospital Generics Business: Building Traction
Complex Hospital Generics Business: Building Traction E Key Highlights Revenue Performance (In ₹ Crore) ❖ Inhalation Anesthesia – Sustaining US Leadership; Building Ex-US Traction 17 % • US – Maintained leadership in Sevoflurane, #1 Rank with 48% value share. • Ex-US Markets – Healthy pickup across
Slide 9: Consumer Healthcare Business: Sustaining Growth Momentum
Consumer Healthcare Business: Sustaining Growth Momentum E Key Highlights Revenue Performance (In ₹ Crore) ❖ Delivered robust growth of 15% in Q1FY27 driven by: 15 % • Power Brands - Delivered 23% YoY growth, contributing 53% of PCH sales. • E-commerce - Delivered 40% YoY growth, contributing 28% of
Slide 10: Focus on Power Brands with Brand Promotion and Marketing
Page 9 Focus on Power Brands with Brand Promotion and Marketing E (In ₹ Cr) Investments in Brand Promotion and Marketing % of PCH 11% 13% 12% 13% 12% sales 148 38 41 131 125 FY24 FY25 FY26 Q1FY26 Q1FY27 (In ₹ Cr) Strong Growth in our Power Brands 22% CAGR 23% 664 538 184 448 149 FY24 FY25 FY26 Q1FY2
Slide 11: AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL
AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL E FY2026 PERFORMANCE Strong profitability and ₹526 Cr. 23% established market position Revenue PAT Margin LEADING MARKET POSITION INTEGRATED SOLUTIONS MARKET POSITION INTEGRATED SOLUTIONS One of the market leaders in the PPL CDMO business
Slide 12: Financials
Piramal Pharma Limited 11
Slide 13: Consolidated Financials Highlights
Consolidated Financials Highlights E Healthy Growth Across Businesses with EBITDA Margin Expansion (in ₹ Cr. or as stated) Particulars Q1FY27 Q1FY26 % Change Revenue from Operations1 2,270 1,934 17% CDMO 1,187 997 19% CHG 743 637 17% PCH 347 302 15% EBITDA 285 165 72% EBITDA Margin 12.5% 8.5% PAT (b
Slide 14: Dial-in Details for Q1FY27 Earnings Conference Call
Dial-in Details for Q1FY27 Earnings Conference Call E Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 12:00 AM Toll free number Conference call (Eastern Time – New York) 18667462133 on 30th July
Slide 15: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi